← All diseases
Blood and bone marrow
Myelodysplastic syndrome
Would you like to receive a message when there is new research about Myelodysplastic syndrome? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above every publication explaining what was investigated — and you receive a message as soon as there is new research on Myelodysplastic syndrome. View what Premium costs.
Publications and studies (1769)
- Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China. (2026/12/01) ♡
- Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. (2026/09/01) ♡
- Insights to provider practice of germline testing for inherited hematologic malignancy predisposition syndromes to inform hematopoietic stem cell transplantation. (2026/08/10) ♡
- The FOLR2-IRF2BP2 axis mediates erythropoiesis impairment by excess folic acid in myelodysplastic neoplasms. (2026/08/10) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Sequential therapy with decitabine and an XPO-1 inhibitor followed by allogeneic hematopoietic stem cell transplantation in MDS with biallelic TP53 inactivation patients : a preliminary case series. (2026/08/10) ♡
- Second primary cancers in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia-cumulative burden without generalized excess cancer risk. (2026/08/09) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers. (2026/08/08) ♡
- SLF2 and SMC5 dysfunction drives HSC aging and predisposes to MDS, defining a new inherited bone marrow failure syndrome. (2026/08/07) ♡
- A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation. (2026/08/07) ♡
- Prognostic factors for early mortality following allogeneic hematopoietic cell transplantation in hematologic malignancies. (2026/08/07) ♡
- Factors influencing patient preferences for pharmacological and non-pharmacological treatment options in chronic health conditions: a systematic review. (2026/08/06) ♡
- METTL14-mediated m(6)A modification of CCNE1 accelerates progression of myelodysplastic syndromes via MAPK-ERK and PI3K-AKT signaling pathways. (2026/08/06) ♡
- Ki-67 Expression in megakaryocytes: A new prognostic marker in Myelodysplastic Syndromes. (2026/08/05) ♡
- Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. [Guidelines for the essential data entry in the European Bone Marrow Transplant Registry]. (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Hematological Malignancies: A Narrative Review of Current and Emerging Evidence. (2026/08/05) ♡
- Transfusion dependency as an independent predictor of mortality in myelodysplastic syndromes: Interaction across IPSS-R risk strata in a retrospective cohort. (2026/08/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification. (2026/08/03) ♡
- Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026). (2026/08/03) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Reversible Intrapulmonary Vascular Dilatation in a Patient Treated With Luspatercept for Myelodysplastic Syndrome. (2026/08/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Inquiry Regarding the Impact of Anemia Adjustment on Cardiovascular Disease Risk in Patients With Myelodysplastic Syndrome. (2026/08/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Successful treatment of VEXAS syndrome with dual ETV6/EZH2 gene mutations by azacitidine: a case report]. (2026/08/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Bone Marrow Failure Syndromes: Clinical and Genetic Characterization in TERT-associated Dyskeratosis Congenita. (2026/08/01) ♡
- Complex Genomic Alterations in TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia Involving EPOR/JAK2 Amplification, ERG Copy Gains, and TCF3 Deletion. (2026/08/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Clinical Characteristics and Diagnosis of Myelodysplastic Syndrome Accompanied by Eosinophilia and Basophilia. (2026/08/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Allogeneic haematopoietic stem cell transplantation for refractory perforating intestinal Behçet disease in a patient with aplastic anaemia: A case report. (2026/07/31) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Diagnostic accuracy of automated hematology analyzer abnormal flags for detecting hematological malignancies: A systematic review and meta-analysis. (2026/07/31) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Pyoderma gangrenosum as a rare manifestation of myelodysplastic syndrome in a pediatric patient: A case report. (2026/07/31) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Female allogeneic hematopoietic cell transplant survivors' perspectives on cervical cancer screening: a retrospective study. (2026/07/30) ♡
- Real-world investigation of germline predisposition to myelodysplastic syndromes. (2026/07/30) ♡
- ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA. (2026/07/30) ♡
- Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL. (2026/07/30) ♡
- Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor. (2026/07/29) ♡
- Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms. (2026/07/29) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. A cross-sectional study using the surveillance, epidemiology, and end results program database to estimate the prevalence of Myelodysplastic Syndrome (MDS) in the United States. (2026/07/29) ♡
- Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease. (2026/07/29) ♡
- Association of Frailty With Transfusions, Hospitalizations, and Survival in Patients With Myelodysplastic Syndrome Initiating Hypomethylating Agents. (2026/07/29) ♡
- The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes. (2026/07/29) ♡
- Transfusion-Independent iron overload in SF3B1-mutant myelodysplastic syndrome case report. (2026/07/28) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Addressing the therapeutic plateau in higher-risk myelodysplastic syndromes: rethinking trial design strategies. (2026/07/27) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Late-onset PSP/FTD-like atypical parkinsonism as a novel phenotype of POLG-related disease: a case report. (2026/07/27) ♡
- Reactive granulomatous dermatitis as a paraneoplastic phenomenon. (2026/07/27) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes. (2026/07/27) ♡
- Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies. (2026/07/26) ♡
- Nonlarge, Low Platelet Component Concentration Fraction: A Novel Platelet Component-Based Screening Marker for Immune Thrombocytopenia. (2026/07/26) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Therapeutic potential of antisense oligonucleotides in hematological malignancies. (2026/07/25) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. PANoptosis in the pathogenesis of myelodysplastic syndromes. (2026/07/24) ♡
- Targeting NAE1 suppresses osteoclastogenesis via dual regulation of ferritinophagy and ACSL3-mediated ferroptosis. (2026/07/24) ♡
- Cytogenetics of Shwachman Diamond syndrome: 27 years report of the Italian cohort and review of the literature. (2026/07/24) ♡
- The NLRC4 Inflammasome Drives Myelodysplastic Syndrome by Linking Epigenetic Reprogramming and Innate Immune Signaling. (2026/07/24) ♡
- Recent trends in hospitalizations for myelodysplastic syndromes and polycythemia vera in England and Wales. (2026/07/24) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.